ArticleRheumatology (Oxford, England)2020
Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus.
Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Is clonal haematopoiesis the missing link between lupus and cardiovascular disease?Rheumatology (Oxford, England) · 2026Review
- Epidemiology of patients with moderate-to-severe SLE in Sweden.Lupus science & medicine · 2025Article
- Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort.Lupus science & medicine · 2025Article
- Rural-urban disparities in hospitalisation for myocardial infarction in systemic lupus erythematosus in the USA.Lupus science & medicine · 2025Article
- Trajectories of disease severity and their clinical outcome in real-world patients with systemic lupus erythematosus.Heliyon · 2024Article
- Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus.Seminars in arthritis and rheumatism · 2024Article
- Vascular damage in systemic lupus erythematosus.Nature reviews. Nephrology · 2024Review
- Anxiety and Depression and Associated Risk Factors among Outpatients with Systemic Lupus Erythematosus: Eastern Province, Saudi Arabia.Clinics and practice · 2024Article
- Characteristics of patients with initial diagnosis of systemic lupus erythematosus in emergency department and their outcomes: a retrospective single-center study.Clinical rheumatology · 2024Article
- In-hospital mortality and associated factors in patients with systemic lupus erythematosus: analysis over more than 11 years in a reference hospital center.Rheumatology international · 2023Article
- Comparison of Contributors to Mortality Differences in SLE Patients with Different Initial Disease Activity: A Larger Multicenter Cohort Study.Journal of clinical medicine · 2023Article
- A bibliometric analysis of T cell and atherosclerosis.Frontiers in immunology · 2022Article
- High Comorbidity Burden in Patients with SLE: Data from the Community-Based Lupus Registry of Crete.Journal of clinical medicine · 2021Article
- Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.Rheumatology (Oxford, England) · 2020Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
objectiveSLE is associated with high risks of cardiovascular disease (CVD) and mortality, and has a wide spectrum of presentations. We investigated whether SLE severity at diagnosis was associated with CVD or mortality risk.
methodsWithin Medicaid (2000-10), we identified patients 18-65 years of age with incident SLE. Initial SLE severity was classified-mild, moderate, or severe-during the baseline year prior to the start of follow-up (incident index date) using a published algorithm based on SLE-related medications and diagnoses. Patients were followed from the index date to the first CVD event or death, disenrollment, loss to follow-up or end of follow-up period. Cox and Fine-Gray regression models, adjusted for demographics and comorbidities accounting for the competing risk of death (for CVD), estimated CVD and mortality risks by baseline SLE severity.
resultsOf 15 120 incident SLE patients, 48.7% had mild initial SLE severity, 33.9% moderate and 17.4% severe. Mean (s.d.) follow-up was 3.3 (2.4) years. After multivariable adjustment, CVD subdistribution hazard ratios (HRSD) were higher for initially severe [HRSD 1.64 (95% CI 1.32, 2.04)] and moderate [HRSD 1.19 (95% CI 1.00, 1.41)] SLE vs mild SLE. Mortality HRs were also higher for initially severe [HR 3.11 (95% CI 2.49, 3.89)] and moderate [HR 1.61 (95% CI 1.29, 2.01)] SLE vs mild SLE.
conclusionSLE patients with high initial severity had elevated mortality and CVD events risks compared with those who presented with milder disease. This has implications for clinical care and risk stratification of newly diagnosed SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.